» Articles » PMID: 33514849

A Novel CD4+ CTL Subtype Characterized by Chemotaxis and Inflammation is Involved in the Pathogenesis of Graves' Orbitopathy

Overview
Date 2021 Jan 30
PMID 33514849
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Graves' orbitopathy (GO), the most severe manifestation of Graves' hyperthyroidism (GH), is an autoimmune-mediated inflammatory disorder, and treatments often exhibit a low efficacy. CD4+ T cells have been reported to play vital roles in GO progression. To explore the pathogenic CD4+ T cell types that drive GO progression, we applied single-cell RNA sequencing (scRNA-Seq), T cell receptor sequencing (TCR-Seq), flow cytometry, immunofluorescence and mixed lymphocyte reaction (MLR) assays to evaluate CD4+ T cells from GO and GH patients. scRNA-Seq revealed the novel GO-specific cell type CD4+ cytotoxic T lymphocytes (CTLs), which are characterized by chemotactic and inflammatory features. The clonal expansion of this CD4+ CTL population, as demonstrated by TCR-Seq, along with their strong cytotoxic response to autoantigens, localization in orbital sites, and potential relationship with disease relapse provide strong evidence for the pathogenic roles of GZMB and IFN-γ-secreting CD4+ CTLs in GO. Therefore, cytotoxic pathways may become potential therapeutic targets for GO.

Citing Articles

Comparative impact of tertiary lymphoid structures and tumor-infiltrating lymphocytes in cholangiocarcinoma.

Chung S, Yeh Y, Huang C, Chiang N, Hsu D, Chan M J Immunother Cancer. 2025; 13(1).

PMID: 39870490 PMC: 11772930. DOI: 10.1136/jitc-2024-010173.


Single-cell transcriptomics in thyroid eye disease.

Ahsanuddin S, Wu A Taiwan J Ophthalmol. 2025; 14(4):554-564.

PMID: 39803402 PMC: 11717346. DOI: 10.4103/tjo.TJO-D-23-00096.


Transcriptomic profiling of thyroid eye disease orbital fat demonstrates differences in adipogenicity and IGF-1R pathway.

Kim D, Kim S, Han J, Belday K, Li E, Mahoney N JCI Insight. 2024; 9(24).

PMID: 39704170 PMC: 11665563. DOI: 10.1172/jci.insight.182352.


Multi-Omics Approaches to Discover Biomarkers of Thyroid Eye Disease: A Systematic Review.

Zhang H, Zhou Y, Yu B, Deng Y, Wang Y, Fang S Int J Biol Sci. 2024; 20(15):6038-6055.

PMID: 39664569 PMC: 11628329. DOI: 10.7150/ijbs.103977.


Advances of IGF-1R inhibitors in Graves' ophthalmopathy.

Wang M, Liu L Int Ophthalmol. 2024; 44(1):435.

PMID: 39578269 DOI: 10.1007/s10792-024-03358-5.


References
1.
Smith T, Hegedus L . Graves' Disease. N Engl J Med. 2016; 375(16):1552-1565. DOI: 10.1056/NEJMra1510030. View

2.
Bahn R . Graves' ophthalmopathy. N Engl J Med. 2010; 362(8):726-38. PMC: 3902010. DOI: 10.1056/NEJMra0905750. View

3.
Taylor P, Zhang L, Lee R, Muller I, Ezra D, Dayan C . New insights into the pathogenesis and nonsurgical management of Graves orbitopathy. Nat Rev Endocrinol. 2020; 16(2):104-116. DOI: 10.1038/s41574-019-0305-4. View

4.
Kahaly G, Riedl M, Konig J, Pitz S, Ponto K, Diana T . Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. Lancet Diabetes Endocrinol. 2018; 6(4):287-298. DOI: 10.1016/S2213-8587(18)30020-2. View

5.
Rajendram R, Taylor P, Wilson V, Harris N, Morris O, Tomlinson M . Combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED): a multicentre, 2 × 2 factorial, double-blind, randomised controlled trial. Lancet Diabetes Endocrinol. 2018; 6(4):299-309. DOI: 10.1016/S2213-8587(18)30021-4. View